224(top 1%)
16.5K(top 1%)
48(top 1%)
127(top 1%)
all documents
doc citations
citing journals

Top Articles

1Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine20156,773
2Patient-derived tumour xenografts as models for oncology drug developmentNature Reviews Clinical Oncology20121,091
3Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trialsLancet Oncology, The20201,034
4Molecular characterization of human prostate carcinoma cell linesProstate2003555
5Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersNature Genetics2017423
6Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung CancerClinical Cancer Research2012405
7Mammary Gland ECM Remodeling, Stiffness, and Mechanosignaling in Normal Development and Tumor ProgressionCold Spring Harbor Perspectives in Biology2011373
8Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium ExperienceJournal of Thoracic Oncology2015357
9Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX StudyJournal of Thoracic Oncology2019324
10Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX studyAnnals of Oncology2018243
11AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem CellsCell Stem Cell2018189
12RAS Mutations in Human Melanoma: A Marker of Malignant ProgressionJournal of Investigative Dermatology1994180
13Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.Journal of Clinical Oncology1995171
14Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung CancerOncologist2015151
15An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between EvaluatorsJournal of Thoracic Oncology2014148
16A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular binsMolecular Oncology2013140
17The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinomaJournal of the American Academy of Dermatology2016133
18Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 studyLancet Oncology, The2015124
19Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancerBritish Journal of Cancer2015123
20Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts2019123
21The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal CancerPLoS ONE2013106
22Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic AlterationsClinical Cancer Research201699
23Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipientsBlood201194
24Collagen architecture in pregnancy-induced protection from breast cancerJournal of Cell Science201387
25Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian CancerMolecular Cancer Therapeutics201685
26Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data BaseCancer201684
27Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast CancerAnnals of Surgical Oncology201581
28Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung CancerClinical Lung Cancer201476
29Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial CarcinomaJournal of Urology202076
30An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung CancerJournal of Thoracic Oncology201671
31Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancerBreast201370
32Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapyAnnals of Oncology201770
33Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockadeOncotarget201770
34Activation of Wnt signaling promotes olaparib resistant ovarian cancerMolecular Carcinogenesis201968
35Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancerCancer201966
36Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 studyLancet Oncology, The201862
37Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosisMolecular and Cellular Biochemistry199961
38Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal CancerClinical Cancer Research201361
39Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 AlterationsJournal of Thoracic Oncology201761
40Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor ReceptorSeminars in Oncology201460
41New basal cell carcinoma susceptibility lociNature Communications201559
42Worldwide Overview of the Current Status of Lung Cancer Diagnosis and TreatmentArchives of Pathology and Laboratory Medicine201258
43Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypesBreast Cancer Research200957
44STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growthOncotarget201457
45ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic EventsJournal of Thoracic Oncology201956
46Spectral karyotype (SKY) analysis of human prostate carcinoma cell linesProstate200352
47Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family OncogenesClinical Cancer Research202152
48From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug DevelopmentJournal of the National Cancer Institute201351
49cMET Exon 14 Skipping: From the Structure to the ClinicJournal of Thoracic Oncology201651
50Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling studyBritish Journal of Cancer200950